Berlex To Launch Menostar As Lowest Dose Estrogen Patch Approved For Osteoporosis Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
Low estrogen dose reduces need for concomitant progestin therapy in women who have a uterus. Berlex will study longer-term use following June 8 FDA approval.
You may also be interested in...
Berlex' Angeliq Approved, Will Launch In Mid-2006
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.
Berlex' Angeliq Approved, Will Launch In Mid-2006
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.
Massachusetts Medicaid Adds Prior Authorization For Elidel, Protopic
State’s decision to require prior authorization for Novartis’ Elidel and Astellas’ Protopic comes several months after FDA requested that labeling for the topical eczema agents include a “black box” warning for potential cancer risk. MassHealth removes prior authorization requirement for Berlex’ estrogen patch Menostar.